Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (71-80 of 155) with videos related to

Pageof 16
Sort By:
Leukemia Research|April 28, 2004
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcomeAnne S Tsao, Hagop Kantarjian, Deborah Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosisAlfonso Quintás-Cardama, Hagop M Kantarjian, Taghi Manshouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 15, 2013
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicinPartow Kebriaei, Kaci Wilhelm, Farhad Ravandi, et al.
Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.
Cancer|July 11, 2008
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitorsDan Jones, Deborah Thomas, C Cameron Yin, et al.
Cancer|September 13, 2007
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 studyElias Jabbour, Hagop Kantarjian, Jorge Cortes, et al.
American Journal of Hematology|November 20, 2014
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibodyElias Jabbour, Susan O'Brien, Xuelin Huang, et al.
Blood|September 24, 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemiasDan Jones, Rajyalakshmi Luthra, Jorge Cortes, et al.
Blood|November 2, 2002
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesJorge Cortes, Maher Albitar, Deborah Thomas, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Pageof 16

Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
Leukemia Research|April 28, 2004
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcomeAnne S Tsao, Hagop Kantarjian, Deborah Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosisAlfonso Quintás-Cardama, Hagop M Kantarjian, Taghi Manshouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 15, 2013
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicinPartow Kebriaei, Kaci Wilhelm, Farhad Ravandi, et al.
Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.
Cancer|July 11, 2008
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitorsDan Jones, Deborah Thomas, C Cameron Yin, et al.
Cancer|September 13, 2007
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 studyElias Jabbour, Hagop Kantarjian, Jorge Cortes, et al.
American Journal of Hematology|November 20, 2014
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibodyElias Jabbour, Susan O'Brien, Xuelin Huang, et al.
Blood|September 24, 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemiasDan Jones, Rajyalakshmi Luthra, Jorge Cortes, et al.
Blood|November 2, 2002
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesJorge Cortes, Maher Albitar, Deborah Thomas, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Pageof 16